medical devices

Market volatility has depressed healthcare valuations. Intuitive Surgical and Abbott Laboratories now trade at attractive multiples, offering long-term investment opportunities.

Abbott met Q1 expectations with $11.2B revenue but cut full-year EPS guidance due to share dilution from Exact Sciences acquisition, triggering 6% stock decline.

J&J transforms from income stock into growth engine with 50% rally in 12 months, backed by innovative medicines and medical device expansion despite 2026 patent cliff.

Abbott Labs beat Q1 earnings but slashed full-year guidance, causing stock to plummet 4.76% to 52-week low of $96.72.

Global ambulatory surgical equipment market projected to double from $7.39B in 2026 to $14.58B by 2035, driven by demand for minimally invasive procedures.

Stereotaxis acquires Robocath for $20M upfront plus $25M in milestones, targeting $2M first-year revenue and breakeven by year three.

With 73 million seniors expected by 2030, Intuitive Surgical's da Vinci robots positioned to capitalize on surging surgical demand through recurring consumable sales.

Avanos Medical to be acquired by American Industrial Partners for $1.27B in all-cash deal at $25/share, 72.1% premium, closing H2 2026.

Global dermatology devices market projected to surge from $14.4B in 2024 to $25.6B by 2030, driven by rising skin cancer rates and aesthetic demand.

BDX and ISRG emerge as defensive healthcare plays during market downturns, offering dividend stability and surgical innovation leadership respectively.

Johnson & Johnson's 63-year dividend streak and AAA rating offer security, but 2.2% yield falls short of 4% income targets, requiring complementary holdings.

Three dividend aristocrats—Enterprise Products Partners, Realty Income, and Medtronic—offer attractive yields and decades-long dividend growth track records for income-seeking investors.

$VTAK plans European Heart Rhythm Association presentation to drive adoption of LockeT device and VIVO 3D imaging system in key markets.

Radnostix posts $13.07M revenue, second-best on record, driven by 21% calibration growth and regained DUF6 assets. Two key products launching 2026.

Merit Medical Systems acquires View Point Medical for $140M, adding breast cancer imaging technology. Expected to dilute 2026 earnings but turn accretive in 2027.

Johnson & Johnson maintains 63-year dividend growth streak, supported by strong pharmaceutical pipeline, $100B revenue projection, and AAA credit rating despite healthcare regulatory pressures.

Altia launches Design 13.5 platform, expanding embedded UI toolchain beyond automotive into medical devices, consumer electronics, and industrial vehicles with enhanced rendering and modular architecture.

Altia releases Design 13.5 platform, expanding embedded UI development capabilities beyond automotive into medical devices, consumer electronics, and industrial markets with advanced visualization and modular architecture features.

Boston Scientific shares fell 9% after Watchman FLX trial met all endpoints but disappointed investors seeking transformative clinical data to accelerate growth.

$BSX shares dropped 9.02% to 52-week lows despite positive WATCHMAN FLX and EKOS trial results, signaling investor caution amid broader growth concerns.